Predict your next investment

Venture Capital
theddfund.com

See what CB Insights has to offer

Investments

26

Portfolio Exits

2

Funds

1

Partners & Customers

5

About Dementia Discovery Fund

The Dementia Discovery Fund is a close collaboration between charity, industry and the government, to provide much-needed investment in innovative dementia research.

Dementia Discovery Fund Headquarter Location

71 Kingsway

London, England, WC2B 6ST,

United Kingdom

44 20 7421 7070

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Dementia Discovery Fund News

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

Apr 27, 2022

Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia AviadoBio to start clinical trials with its gene therapy candidate later this year London, UK, April 27, 2022 — AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announced today that both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted orphan designation to AVB-101, a one-time gene therapy for the treatment of frontotemporal dementia (FTD). AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy designed for FTD patients with mutations in the Progranulin (GRN) gene. AVB-101 is designed to slow or arrest disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore normal progranulin levels. FTD is a debilitating form of early onset dementia that currently has no approved therapies. “Achieving orphan designations in both the US and EU represents an important milestone in bringing AVB-101 to FTD patients who are living with a debilitating disease without treatment options. We are committed to advancing our proprietary gene therapy platform and working with regulatory authorities and the FTD community to bring a desperately needed option to patients. We look forward to initiating clinical trials for AVB-101 later in 2022,” said Lisa Deschamps, CEO, AviadoBio. “FTD is a devastating condition, for patients, their families and friends, for which there is no effective treatment. A one-time treatment of AVB-101 has the potential to supplement the missing gene on a long-term basis, thereby stopping FTD in its tracks. As a clinician who has been treating this patient group for many years, I am looking forward to seeing how this therapeutic candidate performs in clinical studies,” said Prof. Christopher Shaw, Co-founder and Chief Scientific and Clinical Advisor, AviadoBio. Orphan drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the U.S. The EC grants orphan designation to encourage the development of medicines intended for the treatment of a seriously debilitating or life-threatening rare condition, defined as one that affects fewer than five in 10,000 people in the EU. About AviadoBio At AviadoBio1 our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute. AviadoBio’s unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery. AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio. About Frontotemporal Dementia and AVB-101 Frontotemporal dementia (FTD) is one of most common forms of dementia in individuals under the age of 65 (second after Alzheimer’s disease). It affects 50,000 to 60,000 patients in the U.S. and over 100,000 in the E.U and is characterized by a rapid decline in behaviour, executive function and/or language with an average of onset in the mid-50s. Patients experience a change in personality, apathy, loss of empathy, inappropriate social behaviour, and disinhibition. Unfortunately, with time, patients require significant supportive care and survive seven to ten years after disease onset. Currently there are no approved medicines for the treatment of frontotemporal dementia. Approximately 30-40% of FTD cases are familial and linked to autosomal dominant mutations in three genes including GRN (progranulin). AviadoBio’s AVB-101 is an investigational, one-time, adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the GRN gene. AVB-101 is designed to slow or arrest disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore normal progranulin levels. References: Hogan DB, et al. Can J Neurol Sci. 2016;43 Suppl 1:S96-S109 Olney NT, et al. Neurol Clin. 2017;35(2): 339–374 Greaves CV, et al. J Neurol. 2019;266(8):2075–2086 Contact:

Dementia Discovery Fund Investments

26 Investments

Dementia Discovery Fund has made 26 investments. Their latest investment was in AviadoBio as part of their Series A on December 12, 2021.

CBI Logo

Dementia Discovery Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/2/2021

Series A

AviadoBio

$80M

No

11

12/1/2021

Seed VC

AviadoBio

$16.5M

Yes

7

11/25/2021

Seed VC - II

Loqus23 Therapeutics

$9.3M

No

2

7/29/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/2/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/2/2021

12/1/2021

11/25/2021

7/29/2021

6/2/2021

Round

Series A

Seed VC

Seed VC - II

Seed VC

Seed VC

Company

AviadoBio

AviadoBio

Loqus23 Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$80M

$16.5M

$9.3M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

7

2

10

10

Dementia Discovery Fund Portfolio Exits

2 Portfolio Exits

Dementia Discovery Fund has 2 portfolio exits. Their latest portfolio exit was Bicycle Therapeutics on May 23, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/23/2019

IPO

6

2/7/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/23/2019

2/7/2019

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

6

10

Dementia Discovery Fund Fund History

1 Fund History

Dementia Discovery Fund has 1 fund, including Dementia Discovery.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/25/2018

Dementia Discovery

$350M

6

Closing Date

6/25/2018

Fund

Dementia Discovery

Fund Type

Status

Amount

$350M

Sources

6

Dementia Discovery Fund Partners & Customers

5 Partners and customers

Dementia Discovery Fund has 5 strategic partners and customers. Dementia Discovery Fund recently partnered with Bicycle Therapeutics on March 3, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

3/30/2021

Partner

United Kingdom

Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology

Bicycle Therapeutics has achieved the first milestone in its collaboration with Dementia Discovery Fund and the University of Oxford 's ARUK Oxford Drug Discovery Institute

1

5/7/2019

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

7/10/2018

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

6/18/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

2/28/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

3/30/2021

5/7/2019

7/10/2018

6/18/2018

2/28/2017

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United Kingdom

United Kingdom

United Kingdom

United States

United States

News Snippet

Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology

Bicycle Therapeutics has achieved the first milestone in its collaboration with Dementia Discovery Fund and the University of Oxford 's ARUK Oxford Drug Discovery Institute

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Dementia Discovery Fund Team

1 Team Member

Dementia Discovery Fund has 1 team member, including former Chief Executive Officer, Angus Grant.

Name

Work History

Title

Status

Angus Grant

Chief Executive Officer

Former

Name

Angus Grant

Work History

Title

Chief Executive Officer

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.